Jonathan Thomas Lei, Ph.D.
Picture
![Lei](https://cdn.bcm.edu/sites/default/files/profile_photos/jlei.jpeg)
Jonathan Thomas Lei, Ph.D.
Addresses
- Integrative Bioinformatics Laboratory and Proteogenomics Data Analysis Center (Lab)
-
Suite: 600D
Houston, TX 77030
United States
Phone: (713) 798-4852
Education
- BS from Baylor University
- Waco, Texas United States
- Biology
- PhD from Baylor College of Medicine
- Houston, Texas United States
- Translational Biology and Molecular Medicine
Honors & Awards
- Doreen J. Putrah Cancer Research Foundation Scholar-in-Training Award
- American Association for Cancer Research (03/2021)
- Director's Award for Best Scientific Paper
- Translational Biology & Molecular Medicine Retreat and Research Conference Annual Retreat
- Baylor College of Medicine (10/2018)
- SABCS Basic Science Scholar Award
- San Antonio Breast Cancer Symposium (08/2016)
- Excellence in Leadership Award for Educational Outreach
- Translational Biology & Molecular Medicine Program
- Baylor College of Medicine (05/2018)
- Sanofi Scholar-in-Training Award
- American Association for Cancer Research (02/2023)
- Human Proteome Organization (HUPO) Congress Travel Award
- US HUPO (07/2023)
Professional Interests
- Endocrine Therapy Resistance
- Estrogen Receptor Alpha (ESR1) Chromosomal Rearrangements / ESR1 Fusions
- Clinical Proteogenomics
- Computational Approaches and Synthetic Lethality in Cancer
Professional Statement
Predicting synthetic lethality, where the inactivity of two genes leads to cell death, is a promising approach to identify therapeutic vulnerabilities in many cancer types. More recently, incorporation of large-scale genomics data together with traditional RNAi screens have revealed cancer synthetic lethality networks that have prognostic and therapeutic implications. Our lab is developing computational approaches that includes proteogenomics analyses to predict synthetic lethal drug targets across various cancer types that will generate testable therapeutic hypotheses by leveraging large-scale proteomics and phospho-proteomics data from colon, breast, ovarian, and uterine human cancer data sets, in addition to patient-derived xenografts, to complement genomic mutation, amplification, and overexpression data to predict synthetic lethality and drug response. By integrating phospho-level data, this approach will potentially refine the determinants of gene inactivation status and more robustly nominate clinically actionable synthetic lethal targets than examining genomic data alone.Websites
Professional Development
- Functionally diverse ESR1 gene fusions drive endocrine resistance is estrogen receptor positive breast cancer
- Conference (Presenter, 2016)
- Sponsor: San Antonio Breast Cancer Symposium
- Poster Discussion
- Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer
- Conference (Presenter, 2017)
- Sponsor: American Association for Cancer Research Annual Meeting
- Oncogenes and Tumor Suppressors Minisymposium
- ESR1 gene fusions drive endocrine resistance and metastasis in breast cancer
- Conference (Presenter, 2017)
- Sponsor: San Antonio Breast Cancer Symposium
- Spotlight Poster Discussion
- Pan-cancer proteogenomics expands the landscape of therapeutic targets
- Conference (Presenter, 2023)
- Sponsor: American Association for Cancer Research
- Molecular Targets Minisymposium
- Pan-cancer proteogenomics expands the landscape of therapeutic targets
- Conference (Presenter, 2023)
- Sponsor: Human Proteome Organization
- Cancer Proteomics Session
Selected Publications
- Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT...Ellis MJ, Carr SA & NCI CPTAC "Proteogenomics connects somatic mutations to signalling in breast cancer." Nature. 2016 May 25;534(7605):55-62. Pubmed PMID: 27251275
- Haricharan S, Lei J, Ellis M "Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER(+) Breast Cancer." Cancer Cell. 2016 Mar 14;29(3):249-50. Pubmed PMID: 26977876
- Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ "Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer." Cancer Discov. 2017 Oct;7(10):1-16. Pubmed PMID: 28801307
- Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R...Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer." Cell Rep. 2018; Pubmed PMID: 30089255
- Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE "Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets." Oncogene. 2018;37(33):4581-4598. Pubmed PMID: 29748621
- Lei JT, Gou X, Ellis MJ "ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer." Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. Pubmed PMID: 30525098
- Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, Ellis MJ "DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer." Proc Natl Acad Sci U S A. 2018 Nov 29; Pubmed PMID: 30498031
- Lei JT, Gou X, Seker S, Ellis MJ "ESR1 alterations and metastasis in estrogen receptor positive breast cancer." J Cancer Metastasis Treat. 2019;5 Pubmed PMID: 31106278
- Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ "Endocrine Therapy Resistance: New Insights." Breast. 2019 Nov;48(Suppl 1):S26-30. Pubmed PMID: 31839155
- Lei JT, Gou X, Ellis MJ "ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer." Mol Cell Oncol. 2018 Oct 9;5(6) Pubmed PMID: 30525098
- Lei JT, Mazumdar T, Martinez-Moczygemba M "Three lysine residues in the common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling." J Biol Chem. 2011 Nov 18;286(46):40091-103. Pubmed PMID: 21965659
- Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, Lei JT, Moore JP, Tavana G, Lewis LR, Zhu Y, Muzny DM, Gibbs RA, Huston DP "Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1." J Exp Med. 2008 Nov 24;205(12):2711-6. Pubmed PMID: 18955567
- Lei JT, Martinez-Moczygemba M "Separate endocytic pathways regulate IL-5 receptor internalization and signaling." J Leukoc Biol. 2008 Aug;84(2):499-509. Pubmed PMID: 18511572
Memberships
- American Association for Cancer Research
- Associate Member
- American Society for Mass Spectrometry
Log In to edit your profile